Strontium potently inhibits mineralisation in bone-forming primary rat osteoblast cultures and reduces numbers of osteoclasts in mouse marrow cultures
Open Access
- 22 July 2014
- journal article
- research article
- Published by Springer Nature in Osteoporosis International
- Vol. 25 (10) , 2477-2484
Abstract
Summary The basic mechanisms by which strontium ranelate acts on bone are still unclear. We show that an important action of strontium salts is to block calcification in cultures of osteoblasts, the bone-forming cells. These results suggest that strontium treatment could have previously overlooked effects on bone. Introduction The basic mechanisms of action of strontium ranelate (SrR) on bone have remained unclear. We studied the direct actions of Sr2+ salts in functional cultures of osteoblasts and osteoclasts. Methods Cultures of primary osteoblasts from rat calvariae and osteoclast-forming mouse marrow cells were treated continuously with either SrR or strontium chloride (SrCl2). Results Abundant, discretely mineralised ‘trabecular’ bone structures formed in control osteoblast cultures after 14 days. SrR at 0.01, 0.1 and 1 mM inhibited mineralisation to 59, 98 and 100 % (all p < 0.001) of control values, respectively. SrCl2 at the same concentrations caused similar inhibitions. Osteoblast cell numbers and alkaline phosphatase activity were unaltered. SrR dose-dependently reduced the formation of multinucleated osteoclasts from marrow mononuclear cells cultured on dentine for 8 days in the presence of macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor kappa B ligand (RANKL), with a 50 % inhibition occurring at 1 mM; SrCl2 was slightly less effective, eliciting a maximal 30 % inhibition. Corresponding decreases in total resorption pit formation were observed, suggesting Sr2+ salts affect osteoclast formation rather than resorptive activity. Conclusion Our findings are consistent with the documented physicochemical inhibitory action of Sr2+ on mineralisation but contrast with reports that Sr2+ increases osteoblast activity and number in vitro. Our results suggest that rather than acting as an agent that ‘uncouples’ bone formation and resorption, Sr2+ acts as a global inhibitor of bone cell function, with particularly marked effects on mineralisation. The potential effects of long-term Sr2+ on secondary mineralisation in bone deserve investigation.Keywords
This publication has 40 references indexed in Scilit:
- Extracellular ATP Released by Osteoblasts Is A Key Local Inhibitor of Bone MineralisationPLOS ONE, 2013
- Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trialAnnals of the Rheumatic Diseases, 2013
- An Akt-dependent Increase in Canonical Wnt Signaling and a Decrease in Sclerostin Protein Levels Are Involved in Strontium Ranelate-induced Osteogenic Effects in Human OsteoblastsJournal of Biological Chemistry, 2011
- Strontium Enhances Osteogenic Differentiation of Mesenchymal Stem Cells and In Vivo Bone Formation by Activating Wnt/Catenin SignalingStem Cells, 2011
- Strontium Ranelate Decreases Receptor Activator of Nuclear Factor-κB Ligand-Induced Osteoclastic Differentiation In Vitro: Involvement of the Calcium-Sensing ReceptorMolecular Pharmacology, 2010
- Calcium sensing receptor‐dependent and receptor‐independent activation of osteoblast replication and survival by strontium ranelateJournal of Cellular and Molecular Medicine, 2009
- Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosisAnnals of the Rheumatic Diseases, 2008
- Effects of strontium ranelate on spinal osteoarthritis progressionAnnals of the Rheumatic Diseases, 2008
- The calcium-sensing receptor (CaR) is involved in strontium ranelate-induced osteoblast proliferationBiochemical Pharmacology, 2007
- Age and disease-related changes in the mineral of boneCalcified Tissue International, 1993